Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors
Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time
Digital tools offer potential solutions to personalise the patient journey, but more effort is needed to integrate them into current healthcare settings
In the NICHE-3 study, all patients achieved a pathological response
Collaboration is needed to advocate for resilient healthcare systems that can navigate crises and deliver high-quality care to patients with cancer, even in the most trying circumstances
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Results from four early-phase studies show that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially efficacious strategy for the treatment of different diseases including GIST and vascular sarcomas
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.